PPARs and adipocyte function

Molecular and Cellular Endocrinology

Volumn 318, Issue 1-2, 2010, Pages 61-68

  Christodoulides, Constantinos ^a   Vidal Puig, Antonio ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adipocyte; Adipogenesis; PPAR

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ADIPONECTIN; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; FATTY ACID; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JHDM2A DEMETHYLASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN TWIST1; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1;

ADIPOCYTE; ADIPOGENESIS; BINDING AFFINITY; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CONFORMATIONAL TRANSITION; FATTY ACID OXIDATION; GENE EXPRESSION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPODYSTROPHY; MACROPHAGE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SUMOYLATION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSCRIPTION REPRESSION; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 77049090816     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.09.014     Document Type: Review

References (96)

1. Adams M., et al. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272 8 (1997) 5128-5132
2. Agostini M., et al. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 4 4 (2006) 303-311
3. Barak Y., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 4 (1999) 585-595
4. Barak Y., et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 99 1 (2002) 303-308
5. Barbera M.J., et al. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J. Biol. Chem. 276 2 (2001) 1486-1493
6. Barroso I., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 6764 (1999) 880-883
7. Bastie C., et al. Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts. J. Biol. Chem. 274 31 (1999) 21920-21925
8. Bastie C., et al. Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation. J. Biol. Chem. 275 49 (2000) 38768-38773
9. Berger J., et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137 10 (1996) 4189-4195
10. Berger J., et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem. 274 10 (1999) 6718-6725
11. Bergman R.N., et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med. 120 2 Suppl. 1 (2007) S3-S8 discussion S29-S32
12. Cabrero A., et al. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes 50 8 (2001) 1883-1890
13. Chao L., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106 10 (2000) 1221-1228
14. Costet P., et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273 45 (1998) 29577-29585
15. Cypess A.M., et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360 15 (2009) 1509-1517
16. Duan S.Z., et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J. Clin. Invest. 117 3 (2007) 812-822
17. Fajas L., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272 30 (1997) 18779-18789
18. Farmer S.R. Molecular determinants of brown adipocyte formation and function. Genes Dev. 22 10 (2008) 1269-1275
19. Feige J.N., et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 45 2 (2006) 120-159
20. Finck B.N., et al. A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab. 1 2 (2005) 133-144
21. Floyd Z.E., and Stephens J.M. Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation. Obes Res. 12 6 (2004) 921-928
22. Forman B.M., et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 5 (1995) 803-812
23. Gesta S., Tseng Y.H., and Kahn C.R. Developmental origin of fat: tracking obesity to its source. Cell 131 2 (2007) 242-256
24. Gray S.L., et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 55 10 (2006) 2669-2677
25. Grimaldi P.A. The roles of PPARs in adipocyte differentiation. Prog. Lipid Res. 40 4 (2001) 269-281
26. Guerre-Millo M., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275 22 (2000) 16638-16642
27. Hansen J.B., et al. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276 5 (2001) 3175-3182
28. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 18 Suppl. 2 (2002) S10-S15
29. He W., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100 26 (2003) 15712-15717
30. Hostetler H.A., et al. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands. J. Biol. Chem. 280 19 (2005) 18667-18682
31. Hostetler H.A., Kier A.B., and Schroeder F. Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARalpha). Biochemistry 45 24 (2006) 7669-7681
32. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 7121 (2006) 860-867
33. Hu E., et al. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274 5295 (1996) 2100-2103
34. Imai T., et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. U.S.A. 101 13 (2004) 4543-4547
35. Itoh T., et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 15 9 (2008) 924-931
36. Jones J.R., et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 102 17 (2005) 6207-6212
37. Juge-Aubry C.E., et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J. Biol. Chem. 274 15 (1999) 10505-10510
38. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106 4 (2000) 473-481
39. Kersten S., et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103 11 (1999) 1489-1498
40. Kliewer S.A., et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 5 (1995) 813-819
41. Kubota N., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4 4 (1999) 597-609
42. Larsen T.M., Toubro S., and Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?. Int. J. Obes. Relat. Metab. Disord. 27 2 (2003) 147-161
43. Lee S.S., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 6 (1995) 3012-3022
44. Lefebvre P., et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest. 116 3 (2006) 571-580
45. Maeda N., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 9 (2001) 2094-2099
46. Matsusue K., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111 5 (2003) 737-747
47. Medina-Gomez G., et al. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 54 6 (2005) 1706-1716
48. Medina-Gomez G., et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3 4 (2007) pe64
49. Montague C.T., and O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49 6 (2000) 883-888
50. Mueller E., et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J. Biol. Chem. 277 44 (2002) 41925-41930
51. Nagy L., et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 2 (1998) 229-240
52. Nawrocki A.R., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281 5 (2006) 2654-2660
53. Nedergaard J., et al. PPARgamma in the control of brown adipocyte differentiation. Biochim. Biophys. Acta 1740 2 (2005) 293-304
54. Nishino N., et al. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J. Clin. Invest. 118 8 (2008) 2808-2821
55. Norris A.W., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112 4 (2003) 608-618
56. Ohshima T., Koga H., and Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J. Biol. Chem. 279 28 (2004) 29551-29557
57. Okuno A., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101 6 (1998) 1354-1361
58. Oliver Jr. W.R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98 9 (2001) 5306-5311
59. Pan D., et al. Twist-1 is a PPARdelta-inducible, negative-feedback regulator of PGC-1alpha in brown fat metabolism. Cell 137 1 (2009) 73-86
60. Pascual G., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 7059 (2005) 759-763
61. Puigserver P., et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92 6 (1998) 829-839
62. Puri V., et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc. Natl. Acad. Sci. U.S.A. 105 22 (2008) 7833-7838
63. Rangwala S.M., et al. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell 5 4 (2003) 657-663
64. Ren D., et al. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev. 16 1 (2002) 27-32
65. Ricote M., and Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 1771 8 (2007) 926-935
66. Rieusset J., et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes 48 4 (1999) 699-705
67. Rim J.S., et al. Sequestration of thermogenic transcription factors in the cytoplasm during development of brown adipose tissue. J. Biol. Chem. 279 24 (2004) 25916-25926
68. Riserus U., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57 2 (2008) 332-339
69. Rosen E.D., and Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444 7121 (2006) 847-853
70. Rosen E.D., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4 4 (1999) 611-617
71. Savage D.B., Petersen K.F., and Shulman G.I. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 45 5 (2005) 828-833
72. Savage D.B., et al. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J. Clin. Endocrinol. Metab. 90 3 (2005) 1446-1452
73. Schopfer F.J., et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc. Natl. Acad. Sci. U.S.A. 102 7 (2005) 2340-2345
74. Seale P., et al. Transcriptional control of brown fat determination by PRDM16. Cell Metab. 6 1 (2007) 38-54
75. Seale P., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 454 7207 (2008) 961-967
76. Seale P., Kajimura S., and Spiegelman B.M. Transcriptional control of brown adipocyte development and physiological function of mice and men. Genes Dev. 23 7 (2009) 788-797
77. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPAR gamma and human metabolic disease. J. Clin. Invest. 116 3 (2006) 581-589
78. Tai T.A., et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. J. Biol. Chem. 271 47 (1996) 29909-29914
79. Tanaka T., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100 26 (2003) 15924-15929
80. Tateishi K., et al. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 458 7239 (2009) 757-761
81. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77 (2008) 289-312
82. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 7 (1994) 1147-1156
83. Tsai Y.S., et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J. Clin. Invest. 114 2 (2004) 240-249
84. Valmaseda A., et al. Opposite regulation of PPAR-alpha and -gamma gene expression by both their ligands and retinoic acid in brown adipocytes. Mol. Cell Endocrinol. 154 1-2 (1999) 101-109
85. van Beekum O., Fleskens V., and Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17 2 (2009) 213-219
86. van Marken Lichtenbelt W.D., et al. Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 360 15 (2009) 1500-1508
87. Vega R.B., Huss J.M., and Kelly D.P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20 5 (2000) 1868-1876
88. Vidal-Puig A., et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97 11 (1996) 2553-2561
89. Vidal-Puig A.J., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99 10 (1997) 2416-2422
90. Virtanen K.A., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360 15 (2009) 1518-1525
91. Wang Y.X., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 2 (2003) 159-170
92. Willson T.M., et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39 3 (1996) 665-668
93. Xue B., et al. Transcriptional synergy and the regulation of Ucp1 during brown adipocyte induction in white fat depots. Mol. Cell. Biol. 25 18 (2005) 8311-8322
94. Yamashita D., et al. The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 9 11 (2004) 1017-1029
95. Yu J.G., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 10 (2002) 2968-2974
96. Zhang J., et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10703-10708